Advanced search
Publication Cover
Leukemia & Lymphoma Volume 62, 2021 - Issue 13
Submit an article Journal homepage
3,544
Views
7
CrossRef citations to date
0
Altmetric
Original Articles

A 2:1 randomized, open-label, phase II study of selinexor vs. physician’s choice in older patients with relapsed or refractory acute myeloid leukemia

Kendra Sweeta Moffitt Cancer Center, Tampa, FL, USACorrespondence[email protected]
View further author information
,
Bhavana Bhatnagarb Ohio State University, Columbus, OH, USAView further author information
,
Hartmut Döhnerc University of Ulm, Ulm, GermanyView further author information
,
Will Donnelland Sarah Cannon Cancer Center, Nashville, TN, USAView further author information
,
Olga Frankfurte Northwestern University, Chicago, IL, USAView further author information
,
Michael Heuserf Hannover Medical School, Hannover, GermanyView further author information
,
Vamsi Kotag Emory University, Atlanta, GA, USAView further author information
,
Hongtao Liuh University of Chicago, Chicago, IL, USAView further author information
,
Emmanuel Raffouxi Hôpital Saint-Louis, Paris, FranceView further author information
,
Gail J. Robozj Weill Cornell Medicine, New York, NY, USAView further author information
,
Christoph Rölligk Dresden University of Technology, Dresden, GermanyView further author information
,
Margaret M. Showell Johns Hopkins University, Baltimore, MD, USAView further author information
,
Stephen A. Strickland Jr.m Vanderbilt-Ingram Cancer Center, Nashville, TN, USAView further author information
,
Susana Vivesn ICO Badalona-Hospital Germans Trias i Pujol, Badalona, SpainView further author information
,
Shijie Tango Karyopharm Therapeutics, Newton, MA, USAView further author information
,
Thaddeus J. Ungero Karyopharm Therapeutics, Newton, MA, USAView further author information
,
Anita Joshio Karyopharm Therapeutics, Newton, MA, USAView further author information
,
Yao Shenp DarwinHealth Inc, New York, NY, USAView further author information
,
Mariano J. Alvarezp DarwinHealth Inc, New York, NY, USA;q Columbia University, New York, NY, USAView further author information
,
Andrea Califanoq Columbia University, New York, NY, USAView further author information
,
Marsha Crochiereo Karyopharm Therapeutics, Newton, MA, USAView further author information
,
Yosef Landesmano Karyopharm Therapeutics, Newton, MA, USAView further author information
,
Michael Kauffmano Karyopharm Therapeutics, Newton, MA, USAView further author information
,
Jatin Shaho Karyopharm Therapeutics, Newton, MA, USAView further author information
,
Sharon Shachamo Karyopharm Therapeutics, Newton, MA, USAView further author information
,
Michael R. Savonar Vanderbilt University, Nashville, TN, USAView further author information
&
Pau Montesinoss Departamento de Hematologia, Hospital Universitario y Politécnico La Fe, Valencia, Spain;t CIBERONC, Instituto de Salud Carlos III, Madrid, SpainORCID Iconhttps://orcid.org/0000-0002-3275-5593View further author information
ORCID Icon show all
Pages 3192-3203 | Received 30 Sep 2020, Accepted 21 Jun 2021, Published online: 29 Jul 2021

Citations (7)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (1)

Shyam A. Patel. (2023) Precision and strategic targeting of novel mutation-specific vulnerabilities in acute myeloid leukemia: the semi-centennial of 7 + 3. Leukemia & Lymphoma 64:9, pages 1503-1513.
Read now

Articles from other publishers (6)

Huideng Long, Yue Hou, Jun Li, Chunhua Song & Zheng Ge. (2023) Azacitidine Is Synergistically Lethal with XPO1 Inhibitor Selinexor in Acute Myeloid Leukemia by Targeting XPO1/eIF4E/c-MYC Signaling. International Journal of Molecular Sciences 24:7, pages 6816.
Crossref
Piroska Klement, Walter Fiedler, Razif Gabdoulline, Louisa-Kristin Dallmann, Clara Philine Wienecke, Johannes Schiller, Christian Kandziora, Katrin Teich, Bennett Heida, Konstantin Büttner, Maximilian Brandes, Carolin Funke, Martin Wichmann, Basem Othman, Joerg Chromik, Stefanie Amberg, Maxim Kebenko, Vera Schlipfenbacher, Anne Christine Wilke, Franziska Modemann, Melanie Janning, Hubert Serve, Carsten Bokemeyer, Susann Theile, Ute Deppermann, Anne L. Kranich, Arnold Ganser, Felicitas Thol & Michael Heuser. (2022) Molecular response patterns in relapsed/refractory AML patients treated with selinexor and chemotherapy. Annals of Hematology 102:2, pages 323-328.
Crossref
Avinash Patel, Diana Mitrea, Vigneshwaran Namasivayam, Mark A. Murcko, Michael Wagner & Isaac A. Klein. (2022) Principles and functions of condensate modifying drugs. Frontiers in Molecular Biosciences 9.
Crossref
Giulia Pianigiani, Andrea Gagliardi, Federica Mezzasoma, Francesca Rocchio, Valentina Tini, Barbara Bigerna, Paolo Sportoletti, Simona Caruso, Andrea Marra, Sara Peruzzi, Eleonora Petito, Giulio Spinozzi, Sharon Shacham, Yosef Landesman, Concetta Quintarelli, Paolo Gresele, Franco Locatelli, Maria Paola Martelli, Brunangelo Falini & Lorenzo Brunetti. (2022) Prolonged XPO1 inhibition is essential for optimal antileukemic activity in NPM1 -mutated AML . Blood Advances 6:22, pages 5938-5949.
Crossref
Roberta Ranieri, Giulia Pianigiani, Sofia Sciabolacci, Vincenzo Maria Perriello, Andrea Marra, Valeria Cardinali, Sara Pierangeli, Francesca Milano, Ilaria Gionfriddo, Lorenzo Brunetti, Maria Paola Martelli & Brunangelo Falini. (2022) Current status and future perspectives in targeted therapy of NPM1-mutated AML. Leukemia 36:10, pages 2351-2367.
Crossref
J. J. W. M. Janssen, B. Löwenberg, M. Manz, B. J. Biemond, P. E. Westerweel, S. K. Klein, M. Fehr, H. A. M. Sinnige, A. Efthymiou, M. C. J. C. Legdeur, T. Pabst, M. Gregor, M. W. M. van der Poel, D. Deeren, L. W. Tick, M. Jongen-Lavrencic, F. van Obbergh, R. S. Boersma, O. de Weerdt, Y. Chalandon, D. Heim, O. Spertini, G. van Sluis, C. Graux, G. Stüssi, Y. van Norden & G. J. Ossenkoppele. (2022) Addition of the nuclear export inhibitor selinexor to standard intensive treatment for elderly patients with acute myeloid leukemia and high risk myelodysplastic syndrome. Leukemia 36:9, pages 2189-2195.
Crossref

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.